We have been shifting our portfolio by rotating out of long positions in commodity currencies, preferring commodity importers. We believe risks are skewed for EMEA EM commodity currencies to underperform in the months ahead, after having outperformed year-to-date.
This has led us to rotate out of RUB into TRY in the GBI-EM Model Portfolio; eroding carry is likely to curb further RUB appreciation in an environment where oil prices are under downward pressure and policymakers are increasingly uneasy with RUB strength.
In outright trades, we hold long TRY/ZAR, with the ingredients for TRY outperformance against other EMEA EM high yielders in place in our view.
Our preferred TRY relative value expression is against ZAR, with rand valuations uncompelling at current levels given risks of further political noise in the months ahead and a pending Moody’s rating review, and headwinds from falling iron ore prices. In late March, we had moved ZAR to MW (from OW) in the GBI-EM Model Portfolio, as political tensions escalated.
We add short EM vol risk on positive developments this week, selling 1Y USDTRY vols after unexpected CBRT hawkishness, and -1M/+3M vega-neutral calendars in USDBRL to fade the mid-week vol uptick driven by local and NAFTA political noise.
Stay overweight FX in GBI-EM model portfolio, mainly via Latam. Country overnights are TRY, ARS, BRL, and COP.


US Economy Fueled by AI Investment Faces Rising Risks Ahead of Fed Meeting
Global Markets React to Strong U.S. Jobs Data and Rising Yields
Global Bond Selloff Pressures Stocks as Rising Oil Prices Fuel Inflation Fears
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Oil Prices Dip Slightly Amid Focus on Russian Sanctions and U.S. Inflation Data
Gold Prices Slide as Rate Cut Prospects Diminish; Copper Gains on China Stimulus Hopes
Wall Street Analysts Weigh in on Latest NFP Data
U.S. Treasury Yields Expected to Decline Amid Cooling Economic Pressures
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks
China’s Growth Faces Structural Challenges Amid Doubts Over Data
China's Refining Industry Faces Major Shakeup Amid Challenges
U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge
Stock Futures Dip as Investors Await Key Payrolls Data 



